Growth hormone axis
CJC-1295 (DAC)
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
CJC-1295 (DAC) at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 2–4 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Timing
- The DAC form is long-acting, so it's dosed only once or twice a week rather than daily.
- What people report
- Builds over weeks as levels reach steady state.
- Time to steady level
- ~35.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- 8–12 weeks
- Break between
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C165H269N47O46
- Mol. weight
- 3,647.2 Da
- CAS
- 863288-34-0
- PubChem CID
- 91971820
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for CJC-1295 (DAC) describe 2–4 mg per administration. Descriptive only, not a recommendation.
About 6–8 days; the albumin-binding DAC is what stretches it to that range.
Dosing schedule
How CJC-1295 (DAC) is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported rangeThe DAC form is long-acting, so it raises a sustained rise rather than a sharp pulse. Weekly spacing follows the multi-day half-life. | ~30–60 mcg/kg (about 2–4 mg for a 70 kg adult) | Once weekly | SubQ |
What it can be combined with
How CJC-1295 (DAC) is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- CJC-1295 (no DAC)The same peptide in two half-lives; running both stacks one GHRH analog on itself with little added value.Use caution
- SermorelinTwo GHRH analogs on the same receptor — redundant rather than additive.Use caution
- TesamorelinBoth are GHRH analogs; combining them duplicates the same signal.Use caution
- IpamorelinGHRP plus a long-acting GHRH analog; the two axes combine rather than compete.Commonly combined
- MK-677A GHRH analog and a growth-hormone secretagogue act on different steps of the same axis and are commonly discussed together.Commonly combined
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.98× single dose
- Time to steady state
- 35.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Teichman SL et al., JCEM 2006;91:799Single and multiple ascending doses of CJC-1295 with DAC; 30 and 60 mcg/kg were well tolerated with a half-life of ~5.8–8.1 days.